Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCinIT in resectable oral cancer
NL-OMON61378Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in Oral Mucosal Carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Tolerability and efficacy of neoadjuvant intratumoral anti-CTLA-4 combined with systemic anti-PD-1. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on NL-OMON61378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61378.